Literature DB >> 22008005

Incidence of nephrogenic systemic fibrosis at a large university hospital in Sweden.

Alaa Alhadad1, Gunnar Sterner, Åke Svensson, Hussein Alhadad, Peter Leander.   

Abstract

OBJECTIVE: Nephrogenic systemic fibrosis (NSF) is a rare condition that may follow administration of gadolinium-based contrast media (Gd-CM) in patients with renal insufficiency. This study was initiated to determine the incidence of NSF at Skåne University Hospital, Malmö, in Sweden.
MATERIAL AND METHODS: During the period January 2001 to December 2008 10 650 patients underwent magnetic resonance imaging (MRI) examinations. The re-expressed four-variable Modification of Diet in Renal Disease (MDRD) equation was used to calculate the estimated glomerular filtration rate (eGFR). The 272 patients with an eGFR <30 ml/min/1.73 m2 who were given Gd-CM were selected for final analysis. A diagnosis of NSF or other dermatological diagnoses in the 272 patients was searched for in the database of the Departments of Dermatology and Pathology.
RESULTS: The 272 patients, of whom 26 patients were on dialysis, had undergone 406 MRI examinations with Gd-CM. Mean follow-up time was 3.9 (±2.7 SD) years. Assuming a mean body weight of 70 kg, the overall median dose of the 406 examinations with Gd-CM was 0.14 mmol/kg body weight (0.06, 0.34; 2.5-97.5 percentiles). In this retrospective study of patients with eGFR <30 ml/min/1.73 m(2), none developed NSF (the upper 95% confidence limit for zero cases of NSF in the 272 patients was 2.3%).
CONCLUSION: Although it is premature to claim that Gd-CM using the regimen employed in this institution is safe to use in all patients with eGFR <30 ml/min/1.73 m(2), the results.indicate that development of NSF is extremely uncommon.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22008005     DOI: 10.3109/00365599.2011.621142

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  4 in total

1.  Risk of nephrogenic systemic fibrosis in patients with impaired renal function undergoing fixed-dose gadoxetic acid-enhanced magnetic resonance imaging.

Authors:  Ti-Yung Tseng; Jeng-Hwei Tseng; Bing-Shen Huang; Shen-Yen Lin; Chun-Bing Chen; Yi-Wen Fang; Gigin Lin; Ying-Chieh Lai
Journal:  Abdom Radiol (NY)       Date:  2021-03-20

2.  Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis.

Authors:  Sean A Woolen; Prasad R Shankar; Joel J Gagnier; Mark P MacEachern; Lisa Singer; Matthew S Davenport
Journal:  JAMA Intern Med       Date:  2020-02-01       Impact factor: 21.873

Review 3.  Gadolinium and nephrogenic systemic fibrosis: an update.

Authors:  Alex Weller; Joy L Barber; Oystein E Olsen
Journal:  Pediatr Nephrol       Date:  2013-10-22       Impact factor: 3.714

4.  Nephrogenic systemic fibrosis in Denmark--a nationwide investigation.

Authors:  Tina R Elmholdt; Anne B B Olesen; Bettina Jørgensen; Stinne Kvist; Lone Skov; Henrik S Thomsen; Peter Marckmann; Michael Pedersen
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.